FR3100035B1 - Utilisation d'hémoglobine d'annélides in vitro - Google Patents

Utilisation d'hémoglobine d'annélides in vitro Download PDF

Info

Publication number
FR3100035B1
FR3100035B1 FR1909299A FR1909299A FR3100035B1 FR 3100035 B1 FR3100035 B1 FR 3100035B1 FR 1909299 A FR1909299 A FR 1909299A FR 1909299 A FR1909299 A FR 1909299A FR 3100035 B1 FR3100035 B1 FR 3100035B1
Authority
FR
France
Prior art keywords
hemoglobin
vitro
annelid
anelid
organoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1909299A
Other languages
English (en)
Other versions
FR3100035A1 (fr
Inventor
Franck Zal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hemarina SA
Original Assignee
Hemarina SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hemarina SA filed Critical Hemarina SA
Priority to FR1909299A priority Critical patent/FR3100035B1/fr
Priority to PCT/EP2020/073154 priority patent/WO2021032763A1/fr
Priority to EP20757336.1A priority patent/EP4017261A1/fr
Priority to CA3147455A priority patent/CA3147455A1/fr
Priority to US17/636,188 priority patent/US20220287295A1/en
Publication of FR3100035A1 publication Critical patent/FR3100035A1/fr
Application granted granted Critical
Publication of FR3100035B1 publication Critical patent/FR3100035B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

UTILISATION D'HÉMOGLOBINE D'ANNÉLIDES IN VITRO La présente invention se rapporte à un procédé d’analyse d’un échantillon de cellules d’un patient ou d’un organoïde, comprenant : une première étape de mélange de l’échantillon de cellules du patient ou de l’organoïde avec au moins une molécule choisie parmi une globine d’Annélides, un protomère de globine d’Annélides et une hémoglobine extracellulaire d’Annélides, optionnellement, une seconde étape de préparation du mélange obtenu à la première étape, et une troisième étape d’analyse du mélange obtenu à la première ou à la seconde étape. Figure pour l'abrégé : aucune
FR1909299A 2019-08-20 2019-08-20 Utilisation d'hémoglobine d'annélides in vitro Active FR3100035B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR1909299A FR3100035B1 (fr) 2019-08-20 2019-08-20 Utilisation d'hémoglobine d'annélides in vitro
PCT/EP2020/073154 WO2021032763A1 (fr) 2019-08-20 2020-08-19 Utilisation d'hémoglobine d'annélides in vitro
EP20757336.1A EP4017261A1 (fr) 2019-08-20 2020-08-19 Utilisation d'hémoglobine d'annélides in vitro
CA3147455A CA3147455A1 (fr) 2019-08-20 2020-08-19 Utilisation d'hemoglobine d'annelides in vitro
US17/636,188 US20220287295A1 (en) 2019-08-20 2020-08-19 Use of annelid haemoglobin in vitro

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1909299 2019-08-20
FR1909299A FR3100035B1 (fr) 2019-08-20 2019-08-20 Utilisation d'hémoglobine d'annélides in vitro

Publications (2)

Publication Number Publication Date
FR3100035A1 FR3100035A1 (fr) 2021-02-26
FR3100035B1 true FR3100035B1 (fr) 2024-04-26

Family

ID=68281700

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1909299A Active FR3100035B1 (fr) 2019-08-20 2019-08-20 Utilisation d'hémoglobine d'annélides in vitro

Country Status (5)

Country Link
US (1) US20220287295A1 (fr)
EP (1) EP4017261A1 (fr)
CA (1) CA3147455A1 (fr)
FR (1) FR3100035B1 (fr)
WO (1) WO2021032763A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3120521B1 (fr) * 2021-03-15 2024-03-29 Hemarina Gel à base d’hémoglobine d’Annélides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2919785B1 (fr) * 2007-08-09 2017-10-20 Hemarina Sa Utilisation d'une globine, d'un protomere de globine ou d'une hemoglobine extracellulaire pour la preservation d'organes, de tissus, ou de cellules d'organes ou de tissus, ou de culture de cellules
WO2010128159A1 (fr) * 2009-05-07 2010-11-11 Hemarina Nouvelle hémoglobine et ses utilisations
FR2975869B1 (fr) * 2011-05-31 2017-03-03 Hemarina Composition de preservation d'organe et utilisations
AU2015303147A1 (en) * 2014-08-12 2017-02-23 Arsanis Biosciences Gmbh Predicting S. aureus disease

Also Published As

Publication number Publication date
FR3100035A1 (fr) 2021-02-26
EP4017261A1 (fr) 2022-06-29
CA3147455A1 (fr) 2021-02-25
WO2021032763A1 (fr) 2021-02-25
US20220287295A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
FR3100035B1 (fr) Utilisation d'hémoglobine d'annélides in vitro
CN1134539C (zh) 血小板生成素
Vainchenker et al. Heterogeneity in the cellular commitment of a human leukemic cell line: K 562.
HUP0301046A2 (hu) Kinazolinszármazékok tumorok kezelésére, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ATE419009T1 (de) Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
CA2370057A1 (fr) Composition pulverulente pour la decoloration des fibres keratiniques humaines
Lang et al. The accuracy of calculated base excess in blood
Bogdanski et al. Influence of insulin therapy on expression of chemokine receptor CCR5 and selected inflammatory markers in patients with type 2 diabetes mellitus.
Origa et al. α-globin gene quadruplication and heterozygous β-thalassemia: a not so rare cause of thalassemia intermedia
Gao et al. High levels of transgene expression following transduction of long-term NOD/SCID-repopulating human cells with a modified lentiviral vector
FR3040997B1 (fr) Composition de solvant(s) comprenant un melange d'une molecule ayant une fonction sulfoxyde et d'une molecule ayant une fonction amide
FR3101631B1 (fr) Procede de preparation de mercaptans par sulfhydrolyse de sulfures
Hoffman et al. Fetal hemoglobin in polycythemia vera: cellular distribution in 50 unselected patients
Crocker et al. Adhesion receptors involved in the erythroblastic island.
Bienert et al. Standing behavior in horses after inhalation anesthesia with isoflurane (Isoflo) and postanesthetic sedation with romifidine (Sedivet) or xylazine (Rompun)
FR3076713B1 (fr) Utilisation d'hemoglobine d'annelides comme bactericide, notamment pour prevenir et/ou traiter une maladie parodontale
Caspar‐Bauguil et al. A highly conserved phenylalanine in the α, β‐T cell receptor (TCR) constant region determines the integrity of TCR/CD3 complexes
GOTO et al. Binding of several loop diuretics to serum albumin and human serum from patients with renal failure and liver disease
Aizawa et al. Marrow uptake of galactosyl-containing neoglycoproteins: Implications in stem cell homing.
DK0689434T3 (da) Farmaceutiske præparater, der omfatter paracetamol og L-cystein eller en præcursor deraf
FR3060346B1 (fr) Composition d’eclaircissement capillaire comprenant un agent oxydant, du bicarbonate, et au moins 0,5% en poids de derive polyphosphore
FR3136366B1 (fr) Hémoglobine d’Annélides pour son utilisation dans le traitement de la maladie de Fuchs
FR3118712B1 (fr) Composition pour le soin de matières kératiniques
FR3108790B1 (fr) Electrolytes inorganiques mixtes de lithium
Olsen et al. Acute urinary tract obstruction in dyskeratosis congenita.

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20210226

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6